The Department of Pharmaceuticals has formed a new panel to examine how pharmaceutical brands market to doctors and where oversight is falling short. The committee is chaired by NITI Aayog member M Srinivas, with former Union Health Secretary Preeti Sudan and Medanta CMD Naresh Trehan as members, the Ministry of Chemicals and Fertilisers said on Friday.
The review is significant for healthcare marketers because India’s pharma industry still leans heavily on field-force and relationship-driven promotion. Doctors sit at the centre of prescribing decisions, so the rules shaping medical representative visits, educational events and digital doctor outreach affect a large share of marketing budgets.
Two-month deadline
The panel must consult stakeholders, technical and professional experts, domain specialists and institutions, then submit recommendations within two months of its first meeting. That relatively tight timeline signals urgency.
Why it matters
Pharma marketing is a high-trust, high-regulation space. Even small gaps in how brands document interactions with doctors, structure educational content or manage sponsorships can become compliance problems. The committee will assess the existing regulatory framework and identify measures to improve monitoring, supervision and enforcement against unethical pharmaceutical marketing.
Its recommendations are expected to feed into a stronger framework for pharmaceutical companies’ marketing activities and their engagement with healthcare professionals. That means marketing teams may need to prove that every HCP-facing activity has a clear medical or educational purpose.
- Audit HCP outreach now. Check sponsorships, speaker payments and travel support for a clear, documented rationale.
- Separate education from promotion. Keep medical content and brand messaging distinct in doctor-facing campaigns.
- Tighten approval workflows. Build stronger internal documentation if tougher rules arrive quickly.
What happens next
The panel will take inputs from experts and institutions, then offer recommendations aimed at closing enforcement gaps. The final shape of those recommendations could influence medical-device and health-tech brands that follow a similar HCP engagement playbook.
Until then, healthcare marketing teams should treat the review as an early warning. Auditing existing campaigns now and preparing for more transparent disclosure will be cheaper than scrambling after rules change.
Source: The Economic Times
